Is CRISPR Therapeutics (CRSP) Share Price Aligning With Its Long Term Growth Story?

Simply Wall St.04-24

Wondering whether CRISPR Therapeutics at US$55.18 is priced for its potential or already demanding a premium? This article focuses squarely on what the current market value might be telling you. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629562842?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-24 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629562842","market":"sg","top_or_hot":-1,"title":"Is CRISPR Therapeutics (CRSP) Share Price Aligning With Its Long Term Growth Story?","media":"Simply Wall St.","content":"<div>\n<p>Wondering whether CRISPR Therapeutics at US$55.18 is priced for its potential or already demanding a premium? This article focuses squarely on what the current market value might be telling you. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-share-price-aligning-with-its-lo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is CRISPR Therapeutics (CRSP) Share Price Aligning With Its Long Term Growth Story?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs CRISPR Therapeutics (CRSP) Share Price Aligning With Its Long Term Growth Story?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-24 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-share-price-aligning-with-its-lo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering whether CRISPR Therapeutics at US$55.18 is priced for its potential or already demanding a premium? This article focuses squarely on what the current market value might be telling you. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-share-price-aligning-with-its-lo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRSP","symbol_name":"CRISPR Therapeutics AG","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-share-price-aligning-with-its-lo","article_id":"2629562842","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-share-price-aligning-with-its-lo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629562842","pubTimestamp":1777036417,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering whether CRISPR Therapeutics at US$55.18 is priced for its potential or already demanding a premium? This article focuses squarely on what the current market value might be telling you.\nThe stock has seen a 41.1% return over the last year, with a 30 day return of 18.8%, while also showing shorter term volatility such as a 1% decline over the last week and a 5 year return of negative 58.2%.\nRecent headlines around CRISPR Therapeutics continue to keep attention on the company,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRSP":"CRISPR Therapeutics AG","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4139":"生物科技","BK4611":"AI医疗"},"translate_title":"CRISPR Therapeutics(CRSP)的股价与其长期增长故事一致吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"CRSP":1.5},"content_text":"Wondering whether CRISPR Therapeutics at US$55.18 is priced for its potential or already demanding a premium? This article focuses squarely on what the current market value might be telling you. The stock has seen a 41.1% return over the last year, with a 30 day return of 18.8%, while also showing shorter term volatility such as a 1% decline over the last week and a 5 year return of negative 58.2%. Recent headlines around CRISPR Therapeutics continue to keep attention on the company, including ongoing discussion of its gene editing platform and its position among listed biotech peers. This backdrop helps explain why sentiment can swing quickly as investors reassess both opportunity and risk. CRISPR Therapeutics currently holds a valuation score of 3 out of 6. The rest of this article will compare different valuation approaches before finishing with a way to frame valuation that goes beyond any single model.  CRISPR Therapeutics delivered 41.1% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: CRISPR Therapeutics Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes projected future cash flows and discounts them back to today’s dollars to estimate what the business might be worth right now. For CRISPR Therapeutics, the 2 Stage Free Cash Flow to Equity model starts from last twelve month free cash flow of about $345.4 million outflow. Analyst inputs and extrapolated estimates then project free cash flow moving to $204.5 million by 2030. The path includes both negative and positive cash flow years along the way, all expressed in dollars and discounted back to today. Combining these cash flow projections produces an estimated intrinsic value of about $184.14 per share. Compared with the recent share price of $55.18, this DCF output points to an implied discount of roughly 70.0%. On this model, the stock screens as materially undervalued. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests CRISPR Therapeutics is undervalued by 70.0%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks. CRSP Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CRISPR Therapeutics. Approach 2: CRISPR Therapeutics Price vs Book Price to Book, or P/B, is often used for companies where earnings are less consistent, because it focuses on what you are paying relative to the net assets on the balance sheet rather than current profits. In general, higher growth expectations and lower perceived risk can support a higher P/B multiple, while slower growth or higher uncertainty usually point to a lower, more conservative range. That context helps you judge whether a given P/B looks stretched or restrained. CRISPR Therapeutics currently trades on a P/B of 2.77x. This is above the Biotechs industry average of about 2.39x and above the peer group average of 22.82x, which is very high. Simply Wall St also uses a proprietary “Fair Ratio” for P/B, which estimates what a reasonable multiple might be for this specific company after considering factors such as its earnings profile, growth outlook, risks, profit margins, industry and market capitalization. This Fair Ratio approach can be more tailored than a simple comparison with peers or the broad industry, because it adjusts for the company’s own fundamentals instead of assuming all biotechs deserve similar multiples. In this case, there is no Fair Ratio available, so it is not possible to state whether the current 2.77x P/B suggests CRISPR Therapeutics is under or overvalued. Result: ABOUT RIGHT NasdaqGM:CRSP P/B Ratio as at Apr 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies. Upgrade Your Decision Making: Choose your CRISPR Therapeutics Narrative Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a simple story that links what you believe about a company to the numbers behind it. A Narrative is your structured view of a business, where you set assumptions for future revenue, earnings and margins, then connect those assumptions to an estimated fair value that sits behind the share price you see on screen. On Simply Wall St, Narratives are available on the Community page and are used by millions of investors as an accessible tool that ties a company’s story to a financial forecast and then to a clear fair value that can be compared with the current price to help decide whether it may be a time to wait, add or trim. These Narratives refresh when new information such as news or earnings is added, so the fair value view is not static. For CRISPR Therapeutics that can mean one investor building a cautious Narrative that focuses on ongoing cash outflows, while another builds a more optimistic Narrative that prioritizes the gene editing platform and longer term commercial potential. Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying! NasdaqGM:CRSP 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629562842","isCrawlerRequest":true}